Mr. Leventhal developed the area of royalty and synthetic royalty financing (aka "Revenue Interest Financing") for the biopharma, medical device and diagnostics sectors as the co-founder and manager of Paul Capital Healthcare, the first fund established for the purchase and financing of royalty and revenue interests. Subsequent to his 13 years co-managing Paul Capital Healthcare as a principal investor, as a banker, he has demonstrated consistent best-in-class execution for royalty monetizations and revenue interest financings in terms of transaction size, cost of capital and absence of financial covenants and of restrictive operating covenants. Prior to joining Ladenburg Thalmann, he served as a Managing Director and Head of Royalty & Revenue Interest Financing at Houlihan Lokey and is the Managing Member of the merchant bank Royalty/Revenue Interest Capital, LLC. Mr. Leventhal was graduated Magna Cum Laude with an A.B. degree in Economics from Harvard College, and received his MBA with honors and distinction from Harvard Business School. He is on the Board and is an officer of The Children's Brain Tumor Foundation, The Healing Arts Kits, Inc., and Artists 4 Israel, and is a Trustee of the Washington Institute for Near East Policy.
Lionel is not affiliated with the Cambridge Investment Research company and does not have access to client files.